Source and scope
This summary is bounded to the recommendations, population and decisions covered by A consensus-based treatment algorithm for alopecia areata in adolescents and adults. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian AA consensus
Source-attributed clinical priorities
- Confirm nonscarring patchy hair loss and examine scalp, body hair and nails while excluding fungal and scarring disease.
- Assess extent, activity, autoimmune comorbidity and psychological impact before selecting observation or treatment.
- Refer extensive, rapidly progressive, diagnostically uncertain or highly distressing alopecia.
- Exclamation-mark hairs, nail pitting and nonscarring patches support alopecia areata, but fungal and scarring loss must be excluded.
sources for this section:Canadian AA consensus
Practical assessment and management workflow
1
Record onset, activity, body sites, nail change, autoimmune history and psychological impact.
2
Examine scalp and hair shafts with dermoscopy and test for fungus or other disease when uncertain.
3
Discuss observation, local anti-inflammatory treatment and specialist systemic options by extent and age.
4
Photograph consistently and monitor regrowth, relapse and treatment toxicity.
sources for this section:Canadian AA consensus
Safety, red flags and urgent escalation
- Scarring, scale, pustules or inflammation requires prompt diagnostic assessment to prevent permanent loss.
- Screen severe distress, school or work impact and self-harm risk.
- Avoid systemic immunomodulation without infection, pregnancy, laboratory and malignancy risk review.
sources for this section:Canadian AA consensus
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian AA consensus
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian AA consensus
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Alopecia Areata Consensus PanelA consensus-based treatment algorithm for alopecia areata in adolescents and adultsaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.